In December 2019, Chinese researchers identified a novel coronavirus in humans that caused acute respiratory syndrome—
officially called coronavirus disease (COVID-19) as of February 11, 2020. At the beginning of the outbreak, the Mediterranean
countries seemed to be spared from the health and social disaster happened in China. Quickly the spread of the virus ran faster than
forecasts and Italy was unfortunately followed by Spain, France and other countries counting many cases and deaths. The World
Health Organization declaring COVID-19 a pandemic on March 11th, 2020. A retrospective analysis of big data from Google Trend,
using an infodemiology approach, shows how internet traffic search on COVID-19 may figure on the spread curve.
The clinical aspects of COVID-19 raises from poor of mild symptomatic patients to severe respiratory disease which can quickly
lead patients to respiratory failure and admission to intensive care units. Multi-organ symptoms and different types of involvement
other than respiratory have been described.
Nowadays the vaccination is still under investigation and there is not a specific treatment approved for COVID–19, but the
literature highlights the role of Cloroquine and its less toxic derivative Hydroxychloroquine in the therapeutical management of
COVID-19. Those drugs have been proposed as a potential treatment for COVID-19 and clinical trials are undergoing to evaluate this
drug. However these drugs have known oxidative properties that could decrease glutathione levels and may cause severe hemolysis in
G6PD-deficient patients. Deficient G6PD alleles are distributed worldwide; a conservative estimate is that at least 400 million people
carry a mutation in the G6PD gene causing deficiency, the Mediterranean most frequent variant is a class II allele (1-10% of residual
activity). With worldwide spread of COVID-19, also in regions with a high prevalence of G6PD deficiency, physicians should be aware
of this possible correlation